Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 48 of 58, showing 10 Applications out of 576 total, starting on record 471, ending on 480

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

471.

ECCT/17/09/04   A5354
    A5354       Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses   
Principal Investigator(s)
1. Brian Baker
Site(s) in Kenya
KISUMU CRS
 
21-03-2018 View

472.

ECCT/13/04/04   Enteric Study
    A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens with Loperamide for Treatment of Ambulatory Watery Travelers’ Diarrhea, and Azithromycin with and without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea   
Principal Investigator(s)
1. CPT Brook A. Danboise
Site(s) in Kenya
British Army Training Unit, Kenya (BATUK)
 
26-03-2013 View

473.

ECCT/13/07/04   Advanced Kapsosis Sarcoma Chemotherapy Regimens
    A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. WRP/KEMRI - Kericho (Kericho county)
2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county)
 
07-08-2012 View

474.

ECCT/19/10/02   AMC-100
    A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals with Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)   
Principal Investigator(s)
1. NAFTALI WISINDI BUSAKHALA
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTER
 
01-04-2020 View

475.

ECCT/10/09/05   A5225/ HiFLAC
    A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis       A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)   
Principal Investigator(s)
1. Deborah Chepngeno langat
Site(s) in Kenya
1.
 
08-02-2013 View

476.

ECCT/25/08/06   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women   
Principal Investigator(s)
1. Irene Wambui Inwani
Site(s) in Kenya
1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county)
2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county)
3. Kargeno Research & Policy Hub (Kisumu county)
4. KEMRI-CCR-PHRD, Thika site (Kiambu county)
 
15-12-2025 View

477.

ECCT/22/03/06   Sickle Cell Disease
    A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
2. Fredrick Chite Asirwa
3. Bernhards Ogutu
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Research institute (Kisumu county)
3. International Cancer Centre (Uasin Gishu county)
4. CREATES - Strathmore University Medical Centre (Nairobi City county)
 
15-09-2022 View

478.

ECCT/24/03/06   PHOENIx MDR-TB)
    Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)   
Principal Investigator(s)
1. Dr Lucy Chepkurui Koech KOECH
Site(s) in Kenya
1. Kenya medical Research Institute/ Walter Reed Project (Kericho county)
2. Moi university clinic research Centre (Uasin Gishu county)
 
21-05-2024 View

479.

ECCT/17/06/01   MF/PM Phase III
    An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa       
Principal Investigator(s)
1. Jane Mbui
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba sub-county hospital (West Pokot county)
 
04-10-2017 View

480.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
10-06-2019 View